目的 統(tǒng)計(jì)分析2019—2024年南京市第二醫(yī)院抗結(jié)核藥物使用情況及變化趨勢(shì)，以期規(guī)范抗結(jié)核藥物的合理應(yīng)用。方法 對(duì)南京市第二醫(yī)院2019—2024年26種抗結(jié)核藥物銷售金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）及金額排序/ DDDs排序比（B/A）進(jìn)行統(tǒng)計(jì)分析與評(píng)價(jià)。結(jié)果 2019—2024年，南京市第二醫(yī)院抗結(jié)核藥物銷售金額先降后升，注射類銷售金額2024年較2019年增長134.00%，其他口服類下降73.55%，莫西沙星針劑連續(xù)5年排名第1位。一線口服類DDDs值排序一直靠前，變化較大的有乙胺丁醇、阿米卡星及左氧氟沙星等。21種藥物DDC呈下降趨勢(shì)，8種藥物DDC降幅大于75%。莫西沙星針劑、利福平針劑及利奈唑胺B/A遠(yuǎn)小于1；2019—2024年B/A≥1的藥物平均占比在50%左右。8種免費(fèi)抗結(jié)核藥物于2024年消耗量占比均超過40%，免費(fèi)環(huán)絲氨酸、氯法齊明及貝達(dá)喹啉占比均在80%左右。結(jié)論 南京市第二醫(yī)院抗結(jié)核藥物使用基本合理，政府免費(fèi)藥及“4＋7集中采購”藥品的使用，使大部分藥物DDC均有下降，從一定程度上緩解了患者經(jīng)濟(jì)負(fù)擔(dān)，但存在用藥不合理的現(xiàn)象，仍需加強(qiáng)監(jiān)督管理，以期降低結(jié)核耐藥風(fēng)險(xiǎn)。

Objective To investigate anti-tuberculosis drugs usage in The Second Hospital of Nanjing from 2019 to 2024 and analyze its change trend, in order to regulate its rational application. Methods The annual consumption sums, DDDs, DDC and the B/A of anti-tuberculosis drugs in The Second Hospital of Nanjing from 2019 to 2024 were obtained and analyzed. Results From 2019 to 2024, the annual consumption sums of anti-tuberculosis drugs firstly decreased then increased, and consumption sums of injection drugs increased by 134.00% in 2024 compared with 2019, while the other oral drugs decreased by 73.55%. Moxifloxacin for injection ranked top 1 for five consecutive years. The ranks of DDDs of ethambutol, amikacin, and levofloxacin changed markedly and the top ones were always first-line oral anti-tuberculosis drugs. DDC of 21 drugs appeared downtrend, especially 8 drugs declined by more than 75%. The B/A of moxifloxacin for injection, rifampicin for injection, and linezolid tablets were much less than 1, and drugs with B/A≥1 accounted for 50% from 2019 to 2024. In 2024, consume proportions of 8 kinds of free anti-tuberculosis drugs were more than 40%, and among which free cycloserine, clofazimine, and bedaquiline accounted for 80%. Conclusion The application of anti-tuberculosis drugs in The Second Hospital of Nanjing was basically reasonable, and because of the application of free anti-tuberculosis drugs from government and the “4＋7” procurement with quantity, DDC of most of anti-tuberculosis drugs has decreased which could be helpful to relieve economic pressure of patients. Unreasonable applications of anti-tuberculosis drugs still existed, so supervision and management should be strengthened in order to reduce the risk of anti-tuberculosis drugs resistance.

R978.3